India Glycols: Monitoring Agency Report for Q3FY26 on Preferential Issue Proceeds
India Glycols Limited's Monitoring Agency Report for Q3FY25 shows no deviation in the utilization of ₹466.99 crore raised via preferential issue. Funds were used for working capital and general corporate purposes, including term loan repayments, as per the offer document. All objects were completed by Q3FY26.
This is a routine regulatory filing detailing the utilization of previously raised funds. It does not introduce new financial information, strategic changes, or material events that would significantly impact the company's stock or operations.
The report is a routine monitoring agency submission confirming compliance with the utilization of funds from a preferential issue. It does not contain new financial performance data or strategic announcements that would indicate a positive or negative shift.
India Glycols Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025, concerning the utilization of proceeds from its Preferential Issue of Equity Shares. The report, issued by CARE Ratings Limited, confirms that the utilization of funds aligns with the disclosures made in the offer document.
The total issue size was ₹466.99 crore. Of this, ₹350.25 crore was allocated towards augmenting working capital and ₹116.74 crore for general corporate purposes. The report indicates that during Q3FY26, the company utilized funds towards repayment of working capital demand loans, CC utilization, and other short-term borrowings for working capital. Additionally, ₹116.74 crore was utilized towards repayment of term loan installments under the general corporate purposes category.
Both the working capital and general corporate purposes were scheduled for completion by March 31, 2026, and were reported as completed in Q3FY26, with no delays noted. The company's management has confirmed that the utilization of proceeds is as per the offer document, and there have been no material deviations requiring shareholder approval. The Monitoring Agency has not identified any conflict of interest in its role.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.